Skip to main content Accessibility help
×
Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-26T05:16:54.158Z Has data issue: false hasContentIssue false

3 - Alzheimer’s Dementia or Alzheimer’s Disease

What’s the Difference and Why Should We Care?

Published online by Cambridge University Press:  19 January 2024

Daniel Gibbs
Affiliation:
Emeritus of Oregon Health and Science University
Get access

Summary

I now have a special interest in Alzheimer’s disease. For nearly 25 years, I practiced general neurology in Portland, Oregon. Some of my patients had dementia, a progressive neurological disorder that causes severe cognitive impairment affecting memory, language, motivation, and mood, interfering with everyday activities. There are several diseases that can cause dementia, including Lewy body disease, Parkinson’s disease, frontotemporal degeneration, and vascular dementia, but Alzheimer’s disease is the most common cause, accounting for 60–80% of cases. In 2013, I retired because I had developed mild cognitive impairment (MCI) that was soon shown by biomarker testing to be due to early-stage Alzheimer’s disease. I suddenly wore two hats – that of a retired physician with a lot of experience treating Alzheimer’s disease and now a person living with the same disorder.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Gibbs, DM. Early awareness of Alzheimer disease: A neurologist’s personal perspectiveJAMA Neurology 2019; 76: 249. https://doi.org/10.1001/jamaneurol.2018.4910. PMID: 30776065.CrossRefGoogle ScholarPubMed
Honig, LS, Vellas, B, Woodward, M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med 2018; 378: 321330. https://doi.org/10.1056/NEJMoa1705971. PMID: 29365294.CrossRefGoogle ScholarPubMed
Clinical trial of solanezumab for older individuals who may be at risk for memory loss (A4). https://clinicaltrials.gov/ct2/show/NCT02008357 (accessed May 12, 2022).Google Scholar
A donanemab (LY3002813) prevention study in participants with Alzheimer’s disease (TRAILBLAZER-ALZ 3). https://clinicaltrials.gov/ct2/show/NCT05026866 (accessed May 12, 2022).Google Scholar
A study to evaluate the efficacy and safety of gantenerumab in participants at risk for or at the earliest stages of Alzheimer’s disease (AD) (SKYLINE). https://clinicaltrials.gov/ct2/show/NCT05256134 (accessed May 12, 2022).Google Scholar
van Dyck, CH, Swanson, CJ, Aisen, P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med 2023; 388: 921. https://doi.org/10.1056/NEJMoa2212948.CrossRefGoogle ScholarPubMed
AHEAD 3-45 Study: A study to evaluate efficacy and safety of treatment with lecanemab in participants with preclinical Alzheimer’s disease and elevated amyloid and also in participants with early preclinical Alzheimer’s disease and intermediate amyloid. https://clinicaltrials.gov/ct2/show/NCT04468659 (accessed December 29, 2022).Google Scholar
2023 Alzheimer’s Disease Facts and Figures. www.alz.org/media/documents/alzheimers-facts-and-figures.pdf, pages 20–22 (accessed March 27, 2023, open access).Google Scholar
Brookmeyer, R, Abdalla, N, Kawas, CH, Corrada, MM. Forecasting the prevalence of preclinical and clinical Alzheimer’s disease in the United States. Alzheimers Dement 2019; 14: 121129. www.ncbi.nlm.nih.gov/pmc/articles/PMC5803316/ (accessed December 17, 2022, open access).CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×